Navigation Links
China Biologic Products Enters Into Agreement to Acquire 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd.
Date:10/2/2008

tfolio and achieve our geographic expansion plans. After the closing of our acquisition, our combined production of plasma-based products is expected to reach approximately 450 tons per year and our facilities will have a combined capacity to produce 1100 tons per year. More importantly, we expect to achieve significant synergies and economies of scale through consolidation of our sales and administrative teams, increased bargaining power with suppliers and more efficient utilization of resources such as sharing our technological know-how."

Currently, China Biologic is the only approved manufacturer of plasma-based biopharmaceuticals in Shandong Province, which has a population of 93 million. China Biologic currently produces about 200 tons of plasma-based products per year and has 700 tons of annual production capacity. China Biologic had revenues of $32.4 million and net income of $8.2 million in 2007. Qianfeng is one of the largest plasma-based biopharmaceutical companies in China and the only operating manufacturer in Guizhou Province, which has a population of 39 million. Qianfeng produces about 250 tons of products per year with annual production capacity of 400 tons. China Biologic believes that Qianfeng currently has approximately 9.5% market share in China, as compared to the Company's 6.1%, which would result in a combined market share of approximately 15.6%. The top 6 largest plasma-based biopharmaceutical companies in China including Qianfeng have a total market share of approximately 50%.

Qianfeng is in compliance with Good Manufacturing Practices ("GMP") standards, and has been approved by the PRC's State Food and Drug Administration ("SFDA") to produce six types of plasma-based products including Human Albumin, Human Immunoglobulin, Human Intravenous Immunoglobulin, Human Hepatitis B Immunoglobulin, Human Tetanus Immunoglobulin and Human Rabies Immune Globulin.

Qianfeng owns 7 plasma collection stations in Guizhou Province, of whi
'/>"/>

SOURCE China Biologic Products, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. China Technology Announces New Chief Financial Officer
6. China Medical Technologies Reports First Quarter Financial Results
7. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
8. China Technology Announces Entry to the Solar Energy Sector
9. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
10. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
11. China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... with State Biotech Leaders to Develop Blueprint ... Development while Boosting Rhode Island,s Growing Biotech ... R.I., Dec. 14 Several of ... medicine and biotechnology gathered today at Brown ... importance of medical innovation in Rhode Island ...
(Date:12/14/2009)... Decision Resources, one of the world,s ... healthcare issues, finds that, owing to the launches ... market will increase more than sevenfold from $790 ... in the United States, France, Germany, Italy, Spain, ... Pharmacor report entitled Atrial Fibrillation finds ...
(Date:12/11/2009)... miRagen Therapeutics, Inc., a biopharmaceutical company focused on ... for cardiovascular and muscle disease, today announced the ... a crucial role in the progression of amyotrophic ... in neuromuscular synaptic regeneration in mice. The ... the journal Science , reveal miR-206 as ...
(Date:12/11/2009)... Dec. 11 Marrone Bio Innovations (MBI) ... management team. Mr. Chris Hildreth joined MBI as ... responsible for expanding all commercial aspects of the ... Dr. Kin Sing (Ray) Lam joined MBI as ... company,s development efforts in scaling its broad pipeline ...
Breaking Biology Technology:Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 2Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 3Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 4The Atrial Fibrillation Drug Market Will Increase More Than Sevenfold, from $790 Million in 2008 to $6.1 Billion in 2018 2miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease 2Marrone Bio Innovations Announces Two New Executive Appointments 2Marrone Bio Innovations Announces Two New Executive Appointments 3
... WuXi PharmaTech (Cayman) Inc.,(NYSE: WX ), ... development outsourcing company with operations in China and ... Philadelphia facility to,the Company,s expanding biologics testing, cell ... 31, 2008, WuXi will discontinue its U.S.,biologics manufacturing ...
... companies with substantial internal mammalian cell culture ... manufacturing capacity. Contract mammalian cell culture manufacturers ... pressure of increased utilization rates. For these ... understanding critical demand drivers, market factors and ...
... 1, 2008 Imagine a self-powering cell phone that ... waves produced by the user into the energy it ... it may seem thanks to the recent work of ... of Chemical Engineering at Texas A&M University. , Utilizing ...
Other Biology Technology:WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services 2WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services 3WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services 4WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services 5PharmSource and BioProcess Technology Consultants Announce Publication of New Market Report: Cell Culture Manufacturing Capacity: Trends and Outlook through 2013 2Self-powered devices possible, says Texas A&M researcher 2Self-powered devices possible, says Texas A&M researcher 3
(Date:12/11/2009)... PAAs consumer demand for premium fruit increases, growers ... to market. And to boost their bottom line, ... can increase fruit quality while reducing labor costs. ... growers to produce larger, healthier fruit, is among ... significant impact on fruit production overhead, and, ultimately, ...
(Date:12/11/2009)... Western Reserve University has granted an 18-month, exclusive ... portfolio of insulin analogs. The company must reach ... to obtain an exclusive license on therapies designed ... Diabetes is developing treatments that it hopes will ... rapidly growing insulin market. Insulin is a therapeutic ...
(Date:12/11/2009)... 2009 Keystone Symposia on Molecular and Cellular ... five new Keystone Symposia Fellows for 2010. Launched ... early-career life scientists (postdoctoral trainees or assistant professors) ... for one year. Fellows are selected based on ... to promoting diversity in the biomedical and life ...
Breaking Biology News(10 mins):Horizontal string trimmer reduces labor costs, increases peach size 2Case Western Reserve University grants option to startup Thermalin Diabetes Inc. 2Keystone Symposia appoints 5 Fellows as part of diversity in life science initiative 2Keystone Symposia appoints 5 Fellows as part of diversity in life science initiative 3Keystone Symposia appoints 5 Fellows as part of diversity in life science initiative 4Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effec 62681 1Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effec 62681 2Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effec 62681 3Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effec 62681 4Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effec 62681 5Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effec 62681 6Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effec 62681 7Belluck 26amp 3B Fox Law Firm Urges Caution When Buying Toys This Holiday Season 62677 1Belluck 26amp 3B Fox Law Firm Urges Caution When Buying Toys This Holiday Season 62677 2Belluck 26amp 3B Fox Law Firm Urges Caution When Buying Toys This Holiday Season 62677 3New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard To Treat Forms of Blood Cancer 62675 1New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard To Treat Forms of Blood Cancer 62675 2New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard To Treat Forms of Blood Cancer 62675 3New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard To Treat Forms of Blood Cancer 62675 4New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard To Treat Forms of Blood Cancer 62675 5New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard To Treat Forms of Blood Cancer 62675 6New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard To Treat Forms of Blood Cancer 62675 7New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard To Treat Forms of Blood Cancer 62675 8
... Without them, birds could not fly or attract mates. ... one current hypothesis, developmental biologists at University of Wisconsin ... In a previous study, UW anatomy professor John F. ... and bone morphogenetic protein 2 (Bmp2) must be expressed ...
... and tails, sauropod dinosaurs---famous as the Sinclair gasoline logo and ... because they all seem to look alike. , The ... common in North America during the middle of the dinosaur ... by more specialized plant-eaters at the end of that era. ...
... are more likely to bounce back from extreme coastal ... knowledge, according to a report published in Science. , ... valuable insight into handling extreme coastal disasters - inevitable ... by 2030 and global warming continues to exacerbate extreme ...
Other Biology News:Molecular mechanism of feather formation found 2Molecular mechanism of feather formation found 3Skull study sheds light on dinosaur diversity 2Skull study sheds light on dinosaur diversity 3Environmental lessons from tsunami as world's coastal population doubles 2
...
... pLivSelect is a direct antibiotic-based selection ... solely on colony survival, eliminating the need ... inexpensive process provides close to 100% accuracy ... ideal platform for robot colony picking. This ...
... antibiotic-based selection system for recombinant identification. Recombinant ... the need for costly color screening. This ... 100% accuracy in recombinant selection. pLivSelect is ... picking. This cloning kit can be used ...
... PCR plate, Directly compatible with ABI thermal ... for improved sealing characteristics can be ... or cap strips, Certified free of DNase, ... part of Thermo Fisher Scientific, the world ...
Biology Products: